Semisynthetic deoxyharringtonine for treating leukemia in mice and humans
- 2 January 1984
- journal article
- research article
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 2 (5), 327-333
- https://doi.org/10.1002/stem.5530020506
Abstract
The effects of two varieties of semisynthetic deoxyharringtonine on the tumor mass and survival time of mice with murine leukemia were evaluated. Compared to untreated control mice, the survival time of those with murine leukemia increased by 146% (L7212) and 68% (L615) after treatment. The LD50 for deoxyharringtonine variants DH4.8 and DH was determined to be 322 ± 9 mg/kg and 71 ± 1 mg/kg, respectively. Seventeen patients were then treated with either DH or DH4.8; 11% achieved complete remission, 23% achieved partial remission, and an additional 35% had markedly lower leukocyte levels after treatment. Side effects were minimal. It was concluded that deoxyharringtonine is an effective anti‐leukemic agent.Keywords
This publication has 4 references indexed in Scilit:
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976
- Photosynthetic Activities of Spinach Leaf ProtoplastsPlant Physiology, 1975
- Antitumor Alkaloids from Cephalotaxus harringtonia: Structure and ActivityJournal of Pharmaceutical Sciences, 1972
- Structures of homoerythrina alkaloids from cephalotaxus harringtoniaPhytochemistry, 1972